Calamos Advisors
HRMY icon

Calamos Advisors’s Harmony Biosciences HRMY Stock Holding History

Calamos Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-48,952
Closed -$2.7M – 1168
2022
Q4 		$2.7M Sell
48,952
-24,104
-33% -$1.33M 0.01% 761
2022
Q3 		$3.24M Buy
73,056
+13,978
+24% +$682K 0.01% 783
2022
Q2 		$2.88M Buy
+59,078
New +$2.66M 0.01% 854

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Calamos Advisors's HRMY Position: Q1 2023 in Review

Calamos Advisors sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 48,952 shares — an estimated $2.7M sold.

Calamos Advisors first reported a position in HRMY in Q2 2022 and held it in 3 quarters. The position peaked at $3.24M in Q3 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • Calamos Advisors reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • Calamos Advisors sold 48,952 Harmony Biosciences shares in Q1 2023, an estimated $2.7M.
  • Calamos Advisors first reported a position in Harmony Biosciences in Q2 2022 and held it in 3 quarters.
  • Calamos Advisors's Harmony Biosciences position peaked at $3.24M in Q3 2022.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.